| P50 | author | Timothy Synold | Q78536675 |
| | Jaap Verweij | Q98683725 |
| | Alex Sparreboom | Q71780219 |
| P2093 | author name string | Darcy Spicer | |
| | Albert J. ten Tije | |
| | James H. Doroshow | |
| P2860 | cites work | Drug Metabolism and Disposition | Q1261140 |
| | Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8 | Q72710440 |
| | P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia | Q73719640 |
| | A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression | Q74182573 |
| | Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo | Q77151159 |
| | Multidrug resistance in cancer: role of ATP-dependent transporters | Q28208049 |
| | Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. | Q33178094 |
| | The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. | Q33180222 |
| | Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients | Q33180762 |
| | Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. | Q33180771 |
| | Development of multidrug-resistance convertors: sense or nonsense? | Q33180943 |
| | Measurement of fraction unbound paclitaxel in human plasma. | Q33181092 |
| | Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles | Q33181992 |
| | Role of formulation vehicles in taxane pharmacology | Q33182080 |
| | Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation | Q33182379 |
| | Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions | Q33183268 |
| | Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer | Q33185597 |
| | Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors | Q33334889 |
| | A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance | Q33337302 |
| | Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine | Q36031211 |
| | Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay | Q36895194 |
| | Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. | Q36895716 |
| | Paclitaxel pharmacokinetics and pharmacodynamics | Q40435857 |
| | Does P-glycoprotein play a role in anticancer drug pharmacokinetics? | Q40692358 |
| | Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. | Q40729293 |
| | Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype | Q41592100 |
| | Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance | Q41729131 |
| | The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. | Q43643458 |
| | Mechanism-based pharmacokinetic model for paclitaxel | Q43766553 |
| | The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite | Q47710601 |
| | Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions. | Q50523017 |
| | Indirect-response model for the time course of leukopenia with anticancer drugs. | Q52230502 |
| | Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. | Q54061085 |
| | A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. | Q54116953 |
| | In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833 | Q54290439 |
| | Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. | Q55060683 |
| | Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL | Q71046859 |
| | Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer | Q71093076 |
| | Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446 | Q72212408 |
| | Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans | Q72354126 |
| | Identification of P450 enzymes involved in metabolism of verapamil in humans | Q72585757 |
| | Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme | Q72685142 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| | pharmacokinetics | Q323936 |
| | paclitaxel | Q423762 |
| | oncology | Q162555 |
| P304 | page(s) | 291-298 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | Effect of valspodar on the pharmacokinetics of unbound paclitaxel | |
| P478 | volume | 21 | |